Loading organizations...
Bluwave Capital operates as a thesis-driven investment firm specializing in growth equity within the U.S. healthcare sector. The company strategically deploys capital into private technology and services enterprises. Its core focus lies in fostering innovation that enhances operational efficiency and ultimately improves patient outcomes across the healthcare landscape.
The firm was established in 2020 with the insight that targeted capital can significantly impact the evolution of healthcare. This approach stems from a belief in identifying and supporting emerging solutions that address critical needs within the industry. The firm's operational structure supports its specialized investment strategy.
Bluwave Capital partners with growth-stage private healthcare companies seeking expansion capital and strategic guidance. Its vision is to be a catalyst for advancements in healthcare by backing enterprises that promise to make healthcare more accessible, efficient, and effective. The firm aims to build a portfolio of impactful companies that collectively shape the future of health.
Bluwave Capital has 2 tracked investments across 2 companies. The latest tracked deal is $120.0M Series C in Senda Biosciences in August 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 1, 2022 | Senda Biosciences | $120.0M Series C | Flagship Pioneering | Cambridge Innovation Capital, Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment, Qatar Investment Authority, Samsung Life Science Fund, Stage 1 Ventures, State OF Michigan Retirement System |
| May 25, 2021 | Invaio Sciences | $88.9M Series C | Flagship Pioneering | Alexandria Venture Investments, Stage 1 Ventures |
